Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments
Date:3/14/2012

ensure adequate time for any software download that may be necessary.

About LorcaserinLorcaserin is a new chemical entity that is believed to act as a selective serotonin 2C receptor agonist. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area believed to be involved in the control of appetite and metabolism. Arena has patents that cover lorcaserin in the United States, Europe and other jurisdictions that in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

Arena resubmitted to the FDA the lorcaserin NDA in December 2011, and the agency has assigned a new PDUFA target date of June 27, 2012. Eisai Inc. has exclusive rights to market and distribute lorcaserin in the United States subject to FDA approval of the lorcaserin NDA. An MAA for lorcaserin was filed with the EMA in March 2012. Arena currently owns rights to lorcaserin outside of the United States.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, safety, efficacy, mechanism of action, and potential of lorcaserin; the regulatory review of the lorcaserin NDA resubmission and MAA, including the potential timing for the FDA to complete its review; the data, analyses and other information included in the NDA resubmission,
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Wednesday, March 14
2. Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
3. Arena Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
4. Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
5. Arena Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Arena Submits Response to FDA Complete Response Letter for Lorcaserin
7. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
8. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
9. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
10. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
11. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Echo Pharma Acquisition Limited ("Royalty Pharma") announced ... Acceptance Threshold from 90 percent to 50 percent of ... accordance with the terms of the Revised Offer Document ... Under the terms of the Increased Offer, Royalty ... ELN ) for $12.50 per share in cash. The ...
(Date:5/23/2013)... 2013   BioLife Solutions , Inc. (OTC:BLFS), a ... hypothermic storage and cryopreservation freeze ... media manufacturer , today announced its participation at the ... 2013 this week in London ... Dr. Aby J. Mathew, BioLife,s Senior Vice President and ...
(Date:5/23/2013)... PARIS , May 23, 2013  Volcano ... and manufacturer of precision guided therapy tools designed to ... vascular disease, today announced preliminary results from the ADVISE ... S tenosis E valuation) II trial during ... EuroPCR 2013. These prospective results confirm prior retrospective publications, ...
Breaking Medicine Technology:Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5
... N.J., Aug. 31 QRxPharma (ASX: QRX and OTCQX: ... the 13th World Congress of Pain on 31 August, ... titled "Dual Opioid Therapy: Changing the Paradigm" will focus ... Dual Opioid product for moderate to severe acute pain. ...
... PHILADELPHIA, Aug. 31 Shire plc (LSE: ... biopharmaceutical company, today announced its support for inflammatory bowel ... country.  The six fellowships will begin in 2011 and ... of IBD to physicians who recently completed a fellowship ...
Cached Medicine Technology:QRxPharma to Sponsor Symposium at 13th World Congress on Pain Meeting 2QRxPharma to Sponsor Symposium at 13th World Congress on Pain Meeting 3Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide 2Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide 3
(Date:5/23/2013)... Spring and summer have always been motivation for people ... the city between Memphis and Nashville? In the last year ... has transformed the growing area into one of the most ... of vibrant, young professionals you are going to see demand ... owner of The Fight Shop, one of the city’s hottest ...
(Date:5/23/2013)... Jeanne Ettelson, president of Beyond ... and only free OCD support group in Chicago. ... OCD sufferers, the group is lead by psychologists who ... This allows group participants to learn accurate information about ... , “Participants in Beyond OCD’s support group benefit ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 EnvirOasis, ... the contractor and ESCO market is pleased to announce ... Consortium (DLC) Listed LED products. EnvirOasis has been ... fixtures and retrofit kits and has recently brought ... LED (Light Emitting Diode) is energy efficient lighting ...
(Date:5/23/2013)... Symptoms of borderline personality disorder often mimic traits ... But researchers in Canada say they have identified ... personality disorder: a tendency to misinterpret emotions expressed ... processing facial emotions and will see a negative ... a clinical neuropsychologist and assistant professor at the ...
(Date:5/23/2013)... A shortage of a critical tuberculosis drug has hampered ... to contain the spread of the highly infectious lung ... was first used in 1951 and is one of ... first-line treatment for tuberculosis (TB). Patients must take the ... U.S. Centers for Disease Control and Prevention. However, ...
Breaking Medicine News(10 mins):Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 2Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 3Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 3Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2
... asks board member to seek restatement of Beth ... Massbank director Allan,Bufferd should apply the same ... companies to his role on the board of ... group 1199 SEIU United,Healthcare Workers East. Bufferd is ...
... Bulletin Board: GXYF), a leading developer and marketer of,cheese ... today announced that it will host an investor conference ... the 2008 fiscal year at,11:00 a.m. EST on Friday, ... results before the market opens the same day., ...
... board member to seek restatement of Beth Israel Deaconess,Medical ... CEO and,director Robert Lepofsky should apply the same Sarbanes-Oxley ... his role as Vice,Chairperson of the board of CareGroup, ... according to labor group 1199 SEIU,United Healthcare Workers East., ...
... Sodium and salt levels in foods and,beverages are on ... food,and beverage industry. Why? In two words -- health concerns. ... or No Sodium or Salt,Foods and Beverages in the U.S., ... foodservice menu items and beverages. All of,which have been argued ...
... is also available in German . , ... are childless against their will. The microscopic procedure significantly improves ... was discovered by scientists at the University of Bonn together ... of 124 women. Up to now, the desire to have ...
... markets strong, ADA, Mich., Feb. 6 Alticor ... $7.1 billion for the year ended Dec. 31,2007, a ... Company officials attributed the increase to continued growth ... America, a rebound in,China following the long-awaited establishment of ...
Cached Medicine News:Health News:Massbank Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:Galaxy Nutritional Foods Announces Third Quarter FY2008 Earnings Conference Call for Friday, February 8, 2008 2Health News:Brooks Automation Executive and Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:Sodium Content Foods and Beverages Gain Revenues as Americans are Embracing Low- and No-Sodium Campaigns 2Health News:Significantly higher success rates with artificial insemination 2Health News:Alticor's 2007 Global Sales Top $7 Billion 2Health News:Alticor's 2007 Global Sales Top $7 Billion 3Health News:Alticor's 2007 Global Sales Top $7 Billion 4Health News:Alticor's 2007 Global Sales Top $7 Billion 5Health News:Alticor's 2007 Global Sales Top $7 Billion 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: